Alaunos Therapeutics Inc (TCRT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alaunos Therapeutics Inc (TCRT) has a cash flow conversion efficiency ratio of -0.256x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-552.00K) by net assets ($2.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TCRT days of operational coverage to measure how many days the company can operate on defensive assets alone.
Alaunos Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Alaunos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Alaunos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alaunos Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Americore Resources Corp.
V:AMCO
|
-0.236x |
|
Schroder Japan Growth Fund
LSE:SJG
|
0.001x |
|
Brera Holdings PLC Class B Ordinary Shares
NASDAQ:BREA
|
-0.436x |
|
Archies Limited
NSE:ARCHIES
|
0.015x |
|
IMPRENDIROMA S.P.A.
F:Y37
|
N/A |
|
East Side Games Group Inc
TO:EAGR
|
-0.009x |
|
Au Gold Corp
V:AUGC
|
-0.023x |
|
Randgold Exploration
JSE:RNG
|
0.000x |
Annual Cash Flow Conversion Efficiency for Alaunos Therapeutics Inc (2001–2025)
The table below shows the annual cash flow conversion efficiency of Alaunos Therapeutics Inc from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see TCRT market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.15 Million | $-2.87 Million | -1.333x | +44.70% |
| 2024-12-31 | $2.06 Million | $-4.97 Million | -2.410x | +49.58% |
| 2023-12-31 | $6.31 Million | $-30.14 Million | -4.779x | -530.33% |
| 2022-12-31 | $38.55 Million | $-29.23 Million | -0.758x | +28.39% |
| 2021-12-31 | $58.06 Million | $-61.47 Million | -1.059x | -130.24% |
| 2020-12-31 | $123.98 Million | $-57.01 Million | -0.460x | -6.94% |
| 2019-12-31 | $95.01 Million | $-40.85 Million | -0.430x | +25.61% |
| 2018-12-31 | $85.56 Million | $-49.46 Million | -0.578x | -202.35% |
| 2017-12-31 | $-96.81 Million | $-54.67 Million | 0.565x | -25.16% |
| 2016-12-31 | $-77.30 Million | $-58.33 Million | 0.755x | +659355.55% |
| 2015-12-31 | $87.37 Million | $-10.00K | 0.000x | +99.99% |
| 2014-12-31 | $33.84 Million | $-36.65 Million | -1.083x | +10.13% |
| 2013-12-31 | $49.38 Million | $-59.51 Million | -1.205x | +25.95% |
| 2012-12-31 | $48.45 Million | $-78.83 Million | -1.627x | -200.04% |
| 2011-12-31 | $71.61 Million | $-38.84 Million | -0.542x | +15.86% |
| 2010-12-31 | $30.55 Million | $-19.69 Million | -0.645x | -47.35% |
| 2009-12-31 | $28.10 Million | $-12.29 Million | -0.437x | +87.47% |
| 2008-12-31 | $6.74 Million | $-23.52 Million | -3.490x | -389.56% |
| 2007-12-31 | $30.37 Million | $-21.65 Million | -0.713x | -31.16% |
| 2006-12-31 | $26.53 Million | $-14.42 Million | -0.544x | +55.42% |
| 2005-12-31 | $7.20 Million | $-8.78 Million | -1.219x | -450.55% |
| 2004-12-31 | $-21.02K | $-7.31K | 0.348x | -4.28% |
| 2003-12-31 | $-25.69K | $-9.33K | 0.363x | -46.49% |
| 2002-12-31 | $-17.33K | $-11.77K | 0.679x | -94.13% |
| 2001-12-31 | $-2.62K | $-30.26K | 11.570x | -- |
About Alaunos Therapeutics Inc
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. The company develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. It also develops hunTR TCR discovery platform to target driver mutations. Alaunos Th… Read more